Cervical Cancer Vaccine In India

As Cervical cancer is the second-leading cause of deaths among women in India is exploring options to cap prices so that the vaccines to treat cervical cancer become more affordable, official sources have said.

According to the Indian Council of Medical Research's National Cancer Registry Programme (ICMR-NCRP), the estimated number of cervical cancer cases in the country in 2023 was more than 3.4 lakh, the government informed Parliament.

The Centre on Saturday said it is yet to take a decision on the roll-out of human papillomavirus (HPV) vaccination against cervical cancer in the country.

The indigenously developed quadrivalent HPV vaccine may be considered for introduction in the Universal Immunisation programme (UIP) as a two-dose regimen for adolescent girls aged 9-14 years, Rajya Sabha was informed today.

The Serum Institute's made-in-India vaccine against cervical cancer, CERVAVAC, will be available in the market this month at an MRP of Rs 2,000 per vial of two doses, official sources said on Thursday.

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year.

India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 9-14 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr NK Arora sai

The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

Cancer: In this article, we discuss various other cancers that are extremely common.

Cervical Cancer: In this article, we list some of the most common facts about cervical cancer that every woman should be aware of.

Cervical Cancer Vaccine: Here is everything you need to know about Cervical Cancer and its risk and causes.

ANI: India's first indigenously developed quadrivalent Human Papilloma Virus (qHPV) vaccine will be available at an affordable price.

Cervical Cancer: According to DBT, the indigenous vaccination will prove to be inexpensive and accessible.

India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in theaffordable price range of Rs 200-400.

As Cervical cancer is the second-leading cause of deaths among women in India is exploring options to cap prices so that the vaccines to treat cervical cancer become more affordable, official sources have said.

According to the Indian Council of Medical Research's National Cancer Registry Programme (ICMR-NCRP), the estimated number of cervical cancer cases in the country in 2023 was more than 3.4 lakh, the government informed Parliament.

The Centre on Saturday said it is yet to take a decision on the roll-out of human papillomavirus (HPV) vaccination against cervical cancer in the country.

The indigenously developed quadrivalent HPV vaccine may be considered for introduction in the Universal Immunisation programme (UIP) as a two-dose regimen for adolescent girls aged 9-14 years, Rajya Sabha was informed today.

The Serum Institute's made-in-India vaccine against cervical cancer, CERVAVAC, will be available in the market this month at an MRP of Rs 2,000 per vial of two doses, official sources said on Thursday.

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year.

India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 9-14 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr NK Arora sai

The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

Cancer: In this article, we discuss various other cancers that are extremely common.

Cervical Cancer: In this article, we list some of the most common facts about cervical cancer that every woman should be aware of.

Cervical Cancer Vaccine: Here is everything you need to know about Cervical Cancer and its risk and causes.

ANI: India's first indigenously developed quadrivalent Human Papilloma Virus (qHPV) vaccine will be available at an affordable price.

Cervical Cancer: According to DBT, the indigenous vaccination will prove to be inexpensive and accessible.

India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in theaffordable price range of Rs 200-400.